Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in above market’s expectations. Meanwhile, the management revised down its full-year earnings guidance, sending the stock lower in the premarket session.
Revenues for the quarter rose 10% to $6.3 billion, surpassing the average analysts’ estimate of $6.11 billion. The top line was boosted by the US segment, which grew 14%. International business revenues rose 5% during the quarter.
The New York-based firm reported adjusted earnings of $1.18 per share, up from last year’s earnings of $1.01 per share and above Wall Street’s prediction. Net earnings attributable to shareholders climbed to f $1.4 billion or $0.87 per share from $373 million or $0.23 per share last year.
Product-wise, melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24% year-over-year.
“Through strong commercial execution and financial discipline we are establishing a solid foundation from which we can build the leading biopharma company, well-positioned to address the unmet needs of our patients and create long-term shareholder value,” said CEO Giovanni Caforio.
Melanoma drug Yervoy witnessed a 17% revenue growth, while revenues of Anticoagulant Eliquis moved up 24%
Meanwhile, the company lowered its guidance for full-year unadjusted earnings from $3.84 -$3.94 per share to $3.73- $3.83 per share. It raised the adjusted earnings guidance range from $4.10-$4.20 per share to $4.20-$4.30 per share. Research and development expenses are expected to decline in the low-double digits on an unadjusted basis, and in the mid-single digits on an adjusted basis.
The company said it is on track to complete the acquisition of rival pharma company Celgene. Also, preparations are on for the post-acquisition integration.
Shares of Bristol-Myers dropped early Thursday after closing the previous session higher. The stock lost 18% since the beginning of the year and 24% in the last twelve months.
Video game retailer GameStop Corp. (NYSE: GME), which has become the talk of the town after the unprecedented stock rally in recent weeks, reported a narrower loss for the first
The steel industry managed to shrug off the pandemic blues earlier than expected as the recovery in industrial activity pushed up demand. With the vaccination drive and the government’s aggressive
Campbell Soup Company (NYSE: CPB) reported third-quarter 2021 earnings results today. Net sales decreased 11% year-over-year to $1.98 billion, as a result of lapping the demand surge at the onset